CoChat

Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits

Open access
Wong, Chi Kin, Drucker, Daniel J. · 2025 · Journal of Clinical Investigation

The DOI matches its Crossref record; 94 of the 94 references it cites were found in a registry or an index; 93 of the 166 sources its claims cite were checked for support.

Abstract

Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders. Acute and chronic activation of GLP-1 receptor signaling also reduces systemic and tissue inflammation in mice and humans, through weight loss-dependent and -independent mechanisms, actions that may contribute to the expanding spectrum of clinical benefits ascribed to GLP-1 medicines. In this Review, we highlight current understanding of the direct and indirect antiinflammatory effects and mechanisms of GLP-1 medicines in both preclinical and clinical studies, covering emerging concepts, clinical relevance, and areas of uncertainty that require further investigation.

Overview

CoChat Summary

TL;DR

This review argues that GLP-1-based therapies have antiinflammatory effects beyond their metabolic benefits, with evidence from preclinical and clinical studies across many organ systems. It also highlights that both direct immune-cell actions and indirect neural/metabolic mechanisms likely contribute, but the relative importance of each remains uncertain.

Key findings

  • GLP-1 medicines lower inflammatory biomarkers in people with T2D and/or obesity, including plasma CRP; in semaglutide SUSTAIN and PIONEER trials, glucose and weight explained only 20%–60% of the observed CRP reductions.
  • In preclinical models, acute GLP-1R agonism reduces inflammation independent of major weight loss, for example exenatide or semaglutide reduced circulating TNF-α in LPS-challenged mice, and exenatide downregulated TNF and IL1B in human PBMCs.
  • The review highlights organ-specific antiinflammatory signals: in osteoarthritis, semaglutide improved WOMAC score by –41.7 points versus –27.5 with placebo in STEP-9; in MASH, semaglutide resolved steatohepatitis without worsening fibrosis in 63% versus 34% with placebo, and improved fibrosis without worsening steatohepatitis in 37% versus 23%.
  • Clinical kidney data also support antiinflammatory/anti-fibrotic benefit: in FLOW, once-weekly 1 mg semaglutide reduced the primary composite risk by 24% and delayed CKD progression over 4 years.

Methods

  • Narrative review synthesizing preclinical and clinical evidence on GLP-1 medicines and inflammation across intestinal, cardiovascular, liver, kidney, pulmonary, arthritis, and neuroinflammatory contexts.
  • Draws on mouse models, human cell experiments, knockout/lineage-tracing studies, and randomized clinical trials and post hoc analyses; no new primary dataset is reported in the text provided.
  • Main analytic approach is comparative interpretation of direct versus indirect antiinflammatory mechanisms, including weight loss–dependent and weight loss–independent effects.

Limitations

  • The paper states that distinguishing metabolic from non-metabolic antiinflammatory effects will require complementary transgenic models, pair-feeding experiments, and interdisciplinary techniques; this indicates that current evidence is not sufficient to isolate mechanisms.
  • Several mechanistic claims are explicitly uncertain, including the role of specific GLP-1R-expressing cells in heart, lung, liver, kidney, and brain, and whether neural mechanisms explain human biomarker changes.
  • Evident from the text: this is a review, so conclusions depend on the quality and heterogeneity of prior studies rather than a single controlled experiment.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1172/jci194751

Cites

94 of 94 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Antiinflammatory actions of GLP-1 medicines across organs. GLP-1R agonists exert broad antiinflammatory effects in multiple peripheral organs, including the central nervous system, lungs, cardiovascular system, liver, intestine, kidneys, and joints. Evidence from both preclinical and clinical studies supports their antiinflammatory roles in the cardiovascular system, liver, kidneys, and joints. However, the potential antiinflammatory effects of GLP-1 signaling in the central nervous system, lungs, and intestine remain to be fully elucidated and warrant further investigation.
Figure 1 Antiinflammatory actions of GLP-1 medicines across organs. GLP-1R agonists exert broad antiinflammatory effects in multiple peripheral organs, including the central nervous system, lungs, cardiovascular system, liver, intestine, kidneys, and joints. Evidence from both preclinical and clinical studies supports their antiinflammatory roles in the cardiovascular system, liver, kidneys, and joints. However, the potential antiinflammatory effects of GLP-1 signaling in the central nervous system, lungs, and intestine remain to be fully elucidated and warrant further investigation.CC BY · PubMed Central
Figure 2 The endogenous intestinal GLP-1 circuit as a pathogen and inflammation sensor. TLR4 expression on the basolateral surface of enteroendocrine L cells enables them to respond to endotoxins and endogenous inflammatory signals, triggering the release of GLP-1. Within the intestine, locally secreted GLP-1 can act in a paracrine manner on nearby GLP-1R–expressing cells, including IELs, enteric neurons, and vagal afferent neurons. GLP-1 is also released into the portal system and enters the systemic bloodstream, where it functions as a classical endocrine hormone, reaching peripheral organs to modulate inflammation. Alternatively, signals initiated in the intestine may be transmitted through the intestinal neural network, enabling gut-brain communication that indirectly monitors and influences systemic inflammatory processes.
Figure 2 The endogenous intestinal GLP-1 circuit as a pathogen and inflammation sensor. TLR4 expression on the basolateral surface of enteroendocrine L cells enables them to respond to endotoxins and endogenous inflammatory signals, triggering the release of GLP-1. Within the intestine, locally secreted GLP-1 can act in a paracrine manner on nearby GLP-1R–expressing cells, including IELs, enteric neurons, and vagal afferent neurons. GLP-1 is also released into the portal system and enters the systemic bloodstream, where it functions as a classical endocrine hormone, reaching peripheral organs to modulate inflammation. Alternatively, signals initiated in the intestine may be transmitted through the intestinal neural network, enabling gut-brain communication that indirectly monitors and influences systemic inflammatory processes.CC BY · PubMed Central
Figure 3 Inhibitory effects of GLP-1 medicines on immune cell function. GLP-1 medicines generally exert inhibitory effects on immune cell function. Across multiple T cell populations, they suppress the secretion of interferon-γ (IFN-γ). In intraepithelial lymphocytes (IELs) and invariant natural killer T (iNKT) cells, GLP-1 medicines also induce cyclic adenosine monophosphate (cAMP) and cAMP-responsive element–binding protein (CREB), indicating engagement of the cAMP/protein kinase A signaling pathway. In IELs specifically, the activation of GLP-1R signaling suppresses phosphorylation of ζ chain–associated protein kinase 70 (ZAP70) and its downstream target SH2 domain–containing leukocyte protein 76 (SLP-76), leading to dampening of proximal T cell receptor signaling and reduced cytokine transcription. This mechanism may be shared by iNKT and other T cells expressing the GLP-1R. In myeloid cells, GLP-1 medicines also attenuate proinflammatory cytokine release, although these effects appear to be primarily indirect.
Figure 3 Inhibitory effects of GLP-1 medicines on immune cell function. GLP-1 medicines generally exert inhibitory effects on immune cell function. Across multiple T cell populations, they suppress the secretion of interferon-γ (IFN-γ). In intraepithelial lymphocytes (IELs) and invariant natural killer T (iNKT) cells, GLP-1 medicines also induce cyclic adenosine monophosphate (cAMP) and cAMP-responsive element–binding protein (CREB), indicating engagement of the cAMP/protein kinase A signaling pathway. In IELs specifically, the activation of GLP-1R signaling suppresses phosphorylation of ζ chain–associated protein kinase 70 (ZAP70) and its downstream target SH2 domain–containing leukocyte protein 76 (SLP-76), leading to dampening of proximal T cell receptor signaling and reduced cytokine transcription. This mechanism may be shared by iNKT and other T cells expressing the GLP-1R. In myeloid cells, GLP-1 medicines also attenuate proinflammatory cytokine release, although these effects appear to be primarily indirect.CC BY · PubMed Central
Figure 4 Potential cellular targets mediating the antiinflammatory effects of GLP-1 medicines. GLP-1Rs are expressed at low levels in most peripheral organs and often in rare cell types. In osteoarthritis, a well-established inflammatory condition, GLP-1 medicines likely exert their effects through multiple pathways. These may include direct actions on joint tissues such as the synovium and cartilage. Interactions between GLP-1 medicines, the intestinal immune system including IELs, and the gut microbiota may also influence joint inflammation. Additionally, the central nervous system represents another site of GLP-1 action, contributing to the regulation of systemic inflammation through indirect mechanisms. Other common inflammatory diseases and metabolic complications may respond to GLP-1 medicines in a similar manner.
Figure 4 Potential cellular targets mediating the antiinflammatory effects of GLP-1 medicines. GLP-1Rs are expressed at low levels in most peripheral organs and often in rare cell types. In osteoarthritis, a well-established inflammatory condition, GLP-1 medicines likely exert their effects through multiple pathways. These may include direct actions on joint tissues such as the synovium and cartilage. Interactions between GLP-1 medicines, the intestinal immune system including IELs, and the gut microbiota may also influence joint inflammation. Additionally, the central nervous system represents another site of GLP-1 action, contributing to the regulation of systemic inflammation through indirect mechanisms. Other common inflammatory diseases and metabolic complications may respond to GLP-1 medicines in a similar manner.CC BY · PubMed Central

Verification

Claims the paper makes

78 Valid · 3 Not valid · 49 Not checked · 22 Own results and interpretations

88 more claims · 43 with their cited sources checked

Create a free account to see all 152 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 4

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Cited by

See all 112

Metadata

Authors
Wong, C. K., & Drucker, D. J.
Affiliations
  • Lunenfeld-Tanenbaum Research Institute (CA)
  • University of Toronto (CA)
Corresponding author
Drucker, Daniel J.
Venue
Journal of Clinical Investigation
Published
2025-11-03
Volume
135
Issue
21
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W4415855223
Cited by
112
References
92
Citations by year
2026: 111 · 2025: 1
FWCI
15.11
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Investigation (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • Diabetes Canada
  • Novo Nordisk (154321)
  • Canadian Institutes of Health Research (15432_1, 19204)
  • Banting and Best Diabetes Centre, University of Toronto (154321)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
glucagon-like peptide-1, GLP-1 receptor signaling, anti-inflammatory activity, inflammation, type 2 diabetes, obesity, cardiovascular disease, chronic kidney disease, metabolic liver disease, arthritis, substance use disorders, neurodegenerative diseases, weight loss
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Anti-Inflammatory Agents, Diabetes Mellitus, Type 2, Humans, Inflammation, Obesity, Signal Transduction, Mice, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.